These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 11144993)

  • 21. Pharmacodynamic modeling of muscle relaxants: effect of design issues on results.
    Paul M; Fisher DM
    Anesthesiology; 2002 Mar; 96(3):711-7. PubMed ID: 11873049
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients.
    Ornstein E; Lien CA; Matteo RS; Ostapkovich ND; Diaz J; Wolf KB
    Anesthesiology; 1996 Mar; 84(3):520-5. PubMed ID: 8659778
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dose-dependency of pharmacokinetic/pharmacodynamic parameters after intravenous bolus doses of cisatracurium.
    Chen C; Yamaguchi N; Varin F
    Br J Anaesth; 2008 Dec; 101(6):788-97. PubMed ID: 18974056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics and pharmacodynamics of the benzylisoquinolinium muscle relaxants.
    Hull CJ
    Acta Anaesthesiol Scand Suppl; 1995; 106():13-7. PubMed ID: 8533537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics and pharmacodynamics studies of a loading dose of cisatracurium in critically ill patients with respiratory failure.
    Panusitthikorn P; Suthisisang C; Tangsujaritvijit V; Nosoongnoen W; Dilokpattanamongkol P
    BMC Anesthesiol; 2022 Jan; 22(1):32. PubMed ID: 35065599
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of cisatracurium (51W89) and atracurium by infusion in critically ill patients.
    Newman PJ; Quinn AC; Grounds RM; Hunter JM; Boyd AH; Eastwood NB; Pollard BJ; Pearson AJ; Harper NJ; Beale RJ; Sutjarittam M; Elliot JM; Bion JF
    Crit Care Med; 1997 Jul; 25(7):1139-42. PubMed ID: 9233738
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical pharmacology of mivacurium chloride (BW B1090U) infusion: comparison with vecuronium and atracurium.
    Ali HH; Savarese JJ; Embree PB; Basta SJ; Stout RG; Bottros LH; Weakly JN
    Br J Anaesth; 1988 Nov; 61(5):541-6. PubMed ID: 2905143
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cumulative characteristics of atracurium and vecuronium. A simultaneous clinical and pharmacokinetic study.
    Wright PM; Hart P; Lau M; Sharma ML; Gruenke L; Fisher DM
    Anesthesiology; 1994 Jul; 81(1):59-68; discussion 27A. PubMed ID: 7913801
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics and pharmacodynamics of cisatracurium in young and elderly adult patients.
    Sorooshian SS; Stafford MA; Eastwood NB; Boyd AH; Hull CJ; Wright PM
    Anesthesiology; 1996 May; 84(5):1083-91. PubMed ID: 8624002
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disposition of infusions of atracurium and its metabolite, laudanosine, in patients in renal and respiratory failure in an ITU.
    Parker CJ; Jones JE; Hunter JM
    Br J Anaesth; 1988 Nov; 61(5):531-40. PubMed ID: 3207525
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cerebrospinal fluid concentrations of atracurium, laudanosine and vecuronium following clinical subarachnoid hemorrhage.
    Tassonyi E; Fathi M; Hughes GJ; Chiodini F; Bertrand D; Muller D; Fuchs-Buder T
    Acta Anaesthesiol Scand; 2002 Nov; 46(10):1236-41. PubMed ID: 12421196
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atracurium resistance in a critically Ill patient.
    Tschida SJ; Hoey LL; Nahum A; Vance-Bryan K
    Pharmacotherapy; 1995; 15(4):533-9. PubMed ID: 7479210
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Concentration-effect relationship of cisatracurium at three different dose levels in the anesthetized patient.
    Bergeron L; Bevan DR; Berrill A; Kahwaji R; Varin F
    Anesthesiology; 2001 Aug; 95(2):314-23. PubMed ID: 11506100
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical pharmacokinetics of the newer neuromuscular blocking drugs.
    Atherton DP; Hunter JM
    Clin Pharmacokinet; 1999 Mar; 36(3):169-89. PubMed ID: 10223167
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The infusion requirements and recovery characteristics of cisatracurium or atracurium in intensive care patients.
    Pearson AJ; Harper NJ; Pollard BJ
    Intensive Care Med; 1996 Jul; 22(7):694-8. PubMed ID: 8844237
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the infusion requirements and recovery profiles of vecuronium and cisatracurium 51W89 in intensive care unit patients.
    Prielipp RC; Coursin DB; Scuderi PE; Bowton DL; Ford SR; Cardenas VJ; Vender J; Howard D; Casale EJ; Murray MJ
    Anesth Analg; 1995 Jul; 81(1):3-12. PubMed ID: 7598277
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Newer neuromuscular blocking agents: how do they compare with established agents?
    Sparr HJ; Beaufort TM; Fuchs-Buder T
    Drugs; 2001; 61(7):919-42. PubMed ID: 11434449
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic analysis of the time course of effect of atracurium.
    Warwick NR; Graham GG; Torda TA
    Clin Pharmacol Ther; 1995 Apr; 57(4):390-7. PubMed ID: 7712666
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics and pharmacodynamics of atracurium in infants and children.
    Fisher DM; Canfell PC; Spellman MJ; Miller RD
    Anesthesiology; 1990 Jul; 73(1):33-7. PubMed ID: 2360737
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics and pharmacodynamics of atracurium with and without previous suxamethonium administration.
    Donati F; Gill SS; Bevan DR; Ducharme J; Theoret Y; Varin F
    Br J Anaesth; 1991 May; 66(5):557-61. PubMed ID: 2031815
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.